Form 4: Avidity Biosciences Director Exercises Options and Sells Shares

Director Arthur A. Levin exercised stock options and sold shares of Avidity Biosciences, Inc. on November 19, 2024, according to a recent SEC filing.

Summary

• On November 19, 2024, Avidity Biosciences director Arthur A. Levin exercised stock options to acquire 3,323 shares of common stock at a price of $1.24 per share.
• Following the exercise, Mr. Levin sold the same 3,323 shares at a weighted-average price of $42.1224 per share, with individual sales ranging from $40.72 to $43.35.
• After these transactions, Mr. Levin directly owns 14,830 shares and indirectly owns 131,372 shares through a family trust.
• The option exercise and sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 26, 2023.

Sentiment

Score: 5

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the biotechnology industry.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of trading on non-public information.
• The reported transactions are typical for directors who receive stock options as part of their compensation.
• The price range of the sales is within the expected volatility of a biotech stock.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan.
• The sale of shares by a director could be perceived as a negative signal by some investors, but the pre-arranged nature mitigates this concern.

Key Dates

Keywords

Avidity Biosciences, stock options, insider trading, SEC Form 4, Rule 10b5-1, share sale, director, RNA